<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00272493</url>
  </required_header>
  <id_info>
    <org_study_id>A5220</org_study_id>
    <secondary_id>10148</secondary_id>
    <secondary_id>ACTG A5220</secondary_id>
    <nct_id>NCT00272493</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of an Adjuvant in Improving Immune Response to Hepatitis B Virus Vaccine in HIV Infected Individuals</brief_title>
  <official_title>Improving Immune Response to Hepatitis B Vaccine in HIV-positive Subjects Using Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) as a Vaccine Adjuvant: A Phase II Open-Label Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a naturally occurring substance
      that is made by the body in response to infection or inflammation, and greatly improves
      cellular immune responses. The purpose of this study is to evaluate the safety and
      effectiveness of GM-CSF as an adjuvant to improve the immune response to hepatitis B virus
      (HBV) vaccination in HIV infected individuals.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Highly active antiretroviral therapy (HAART) has greatly improved the life of HIV infected
      individuals. Before the introduction of HAART, the impact of HBV infection and liver disease
      was less prominent due to the rapid progression to AIDS. However, with the use of HAART,
      liver disease has become a leading cause of death in HIV infected individuals; therefore,
      prevention of HBV infection is essential. Most HIV infected people respond poorly to HBV
      vaccines. GM-CSF is a cytokine produced primarily by activated T and B cells and has been
      used extensively as a hematopoietic growth factor. GM-CSF increases neutrophil count,
      improves antigen-presenting cell function, and is involved in the development and improvement
      of cellular immune responses. Past research has shown that GM-CSF improves the immune
      response to HBV vaccination in people with kidney disease. The purpose of this study is to
      evaluate the safety and effectiveness of GM-CSF as an adjuvant to improve the immune response
      to HBV vaccination in HIV infected individuals.

      This study will last 60 weeks. Participants will be randomly assigned to 1 of 2 arms. Arm A
      participants will receive 40 mcg of HBV vaccine at study entry, Week 4, and Week 12. Arm B
      participants will receive 40 mcg of HBV vaccine and 250 mcg of GM-CSF at study entry, Week 4,
      and Week 12. Participants will be stratified by their screening HIV-1 viral load. After
      completing the vaccination series, study visits will occur at Weeks 16, 36, and 60. Blood
      collection, a physical exam, and liver function and hepatitis antibody tests will be
      completed at all study visits. Telephone follow-up by study staff will occur 48 to 96 hours
      post-vaccination.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quantitative hepatitis B surface antibody (HBsAb)</measure>
    <time_frame>At Week 16</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of Grade 3 or higher adverse events (including hypersensitivity reaction) related to study regimens and HIV viral load increase greater than 1 log(10)</measure>
    <time_frame>Throughout the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quantitative HBsAb 24 and 48 weeks after completion of HBV vaccination series</measure>
    <time_frame>At Weeks 36 and 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBsAb response, defined as titer greater than 10 mlU/ml at 4, 24, and 48 weeks after completion of HBV vaccination series</measure>
    <time_frame>At Weeks 16, 36, and 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in HIV viral load from baseline</measure>
    <time_frame>At Weeks 4, 16, and 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in white blood cell and absolute neutrophil count from baseline</measure>
    <time_frame>At Weeks 4, 16, and 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Grade 2 or higher adverse events</measure>
    <time_frame>Throughout the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in CD4 count from baseline</measure>
    <time_frame>At Weeks 4, 16, and 60</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm A participants will receive 40 mcg of HBV vaccine at study entry, Week 4, and Week 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm B participants will receive 40 mcg of HBV vaccine and 250 mcg of GM-CSF at study entry, Week 4, and Week 12.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hepatitis B virus vaccine with GM-CSF adjuvant</intervention_name>
    <description>Arm B participants will receive 40 mcg of HBV vaccine and 250 mcg of GM-CSF at study entry, Week 4, and Week 12.</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hepatitis B virus vaccine</intervention_name>
    <description>Arm A participants will receive 40 mcg of HBV vaccine at study entry, Week 4, and Week 12.</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV infected

          -  CD4 count of 200 cells/mm3 or more within 30 days prior to study entry

          -  HIV-1 RNA viral load value obtained within 30 days prior to study entry

          -  Received HAART for at least 8 weeks prior to study entry OR not on HAART within 8
             weeks prior to study entry with no plans to start HAART during the study. Participants
             receiving HAART must be on stable therapy as defined by the protocol.

          -  Negative hepatitis B core total antibody (HBcAb total), qualitative hepatitis B
             surface antibody (HBsAb), and hepatitis B surface antigen (HBsAg) tests within 30 days
             prior to study entry

          -  Negative hepatitis C virus (HCV) antibody test, completed within 30 days prior to
             study entry

          -  Willing to use acceptable forms of contraception

        Exclusion Criteria:

          -  HCV antibody or HCV RNA positive at any time prior to study entry

          -  Previously vaccinated against HBV

          -  Use of any systemic antineoplastic or immunomodulatory treatment, systemic
             corticosteroids, vaccines, interleukins, interferons, growth factors, or intravenous
             immune globulin within 30 days prior to study entry

          -  Known allergy or sensitivity to any component of the study drugs

          -  Active drug or alcohol dependence that would interfere with participation in the study

          -  Any mental illness that may interfere with the study

          -  Serious illness requiring systemic treatment or hospitalization. Participants who
             complete therapy or are clinically stable on therapy for at least 14 days prior to
             study entry are not excluded.

          -  Body weight less than 50 kg (110 lbs)

          -  Abnormal lab values

          -  Pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Judith A. Aberg, MD</last_name>
    <role>Study Chair</role>
    <affiliation>New York University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edgar (Turner) Overton, MD</last_name>
    <role>Study Chair</role>
    <affiliation>AIDS Clinical Trials Unit, Washington University at St. Louis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University CRS</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-3015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush Univ. Med. Ctr. ACTG CRS</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington U CRS</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63108-2138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NY Univ. HIV/AIDS CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016-6481</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Rochester ACTG CRS</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Rochester ACTG CRS</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Cincinnati CRS</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267-0405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case CRS</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5083</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MetroHealth CRS</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109-1998</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State Univ. AIDS CRS</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington AIDS CRS</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R, Snydman DR. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis. 2001 Feb 1;32(3):492-7. Epub 2001 Jan 23.</citation>
    <PMID>11170959</PMID>
  </reference>
  <reference>
    <citation>Laurence JC. Hepatitis A and B immunizations of individuals infected with human immunodeficiency virus. Am J Med. 2005 Oct;118 Suppl 10A:75S-83S. Review.</citation>
    <PMID>16271546</PMID>
  </reference>
  <reference>
    <citation>Sasaki Md, Foccacia R, de Messias-Reason IJ. Efficacy of granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant for hepatitis B virus in patients with HIV infection. Vaccine. 2003 Nov 7;21(31):4545-9.</citation>
    <PMID>14575766</PMID>
  </reference>
  <reference>
    <citation>Thio CL, Seaberg EC, Skolasky R Jr, Phair J, Visscher B, Mu√±oz A, Thomas DL; Multicenter AIDS Cohort Study. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet. 2002 Dec 14;360(9349):1921-6.</citation>
    <PMID>12493258</PMID>
  </reference>
  <results_reference>
    <citation>Overton ET, Kang M, Peters MG, Umbleja T, Alston-Smith BL, Bastow B, Demarco-Shaw D, Koziel MJ, Mong-Kryspin L, Sprenger HL, Yu JY, Aberg JA. Immune response to hepatitis B vaccine in HIV-infected subjects using granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant: ACTG study 5220. Vaccine. 2010 Aug 2;28(34):5597-604. doi: 10.1016/j.vaccine.2010.06.030. Epub 2010 Jun 23.</citation>
    <PMID>20600512</PMID>
  </results_reference>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2006</study_first_submitted>
  <study_first_submitted_qc>January 4, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2006</study_first_posted>
  <disposition_first_submitted>September 8, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>September 8, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 9, 2009</disposition_first_posted>
  <last_update_submitted>May 17, 2012</last_update_submitted>
  <last_update_submitted_qc>May 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Treatment Experienced</keyword>
  <keyword>Treatment Naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

